* documented sars-cov-2 infection ongoing or that occurred less than 2 months ago * known clinical allergy to polyethylene glycol (peg) * platelet \<50 giga(g) g/l or neutrophils \<0.5 g/l at time of vaccination * vaccination apart from influenza virus within 4 weeks from the 1st injection or planning to receive an approved vaccine 4 weeks after the last injection * vaccination against influenza virus within 14 days before first injection * any hemorrhagic trouble considered as a contraindication to intramuscular injection * history of severe adverse event after a vaccine administration including anaphylaxis and associated symptoms such as rash, respiratory issues, angioedema and abdominal pain, or history of allergic reaction that could be exacerbated by a vaccine component * participant vaccinated against tuberculosis within the past year * participant ill or febrile (body temperature ≥38°c) in the previous 72 hours with symptoms suggesting the presence of covid-19. * allergy to any component of the vaccine or history of severe allergy (anaphylactic type) * treatment received for covid-19 infection (60 days prior to 1st injection). * known hiv, hcv or hbv infection. * use of experimental ig, experimental monoclonal antibodies or convalescent anti-covid-19 serum within 90 days prior to study entry * pregnant, breast-feeding or positive pregnancy test at inclusion visit. * participation in a vaccination trial * participation in other research without investigator's consent research within 4 weeks prior to the inclusion visit and for the duration of the trial translated with deepl.com (free version)

* documented sars-cov-2 infection ongoing or that occurred less than 2 months ago * known clinical allergy to polyethylene glycol (peg) * platelet \<50 giga(g) g/l or neutrophils \<0.5 g/l at time of vaccination * vaccination apart from influenza virus within 4 weeks from the 1st injection or planning to receive an approved vaccine 4 weeks after the last injection * vaccination against influenza virus within 14 days before first injection * any hemorrhagic trouble considered as a contraindication to intramuscular injection * history of severe adverse event after a vaccine administration including anaphylaxis and associated symptoms such as rash, respiratory issues, angioedema and abdominal pain, or history of allergic reaction that could be exacerbated by a vaccine component * participant vaccinated against tuberculosis within the past year * participant ill or febrile (body temperature ≥38°c) in the previous 72 hours with symptoms suggesting the presence of covid-19. * allergy to any component of the vaccine or history of severe allergy (anaphylactic type) * treatment received for covid-19 infection (60 days prior to 1st injection). * known hiv, hcv or hbv infection. * use of experimental ig, experimental monoclonal antibodies or convalescent anti-covid-19 serum within 90 days prior to study entry * pregnant, breast-feeding or positive pregnancy test at inclusion visit. * participation in a vaccination trial * participation in other research without investigator's consent research within 4 weeks prior to the inclusion visit and for the duration of the trial translated with deepl.com (free version)

* documented sars-cov-2 infection ongoing or that occurred less than 3 months ago * known clinical allergy to polyethylene glycol (peg) * pregnant woman during first pregnancy quarter or lactating woman * platelet \<50 giga(g) g/l or neutrophils \<0.5 g/l at time of vaccination * vaccination within 4 weeks from the 1st injection or planning to receive an approved vaccine 4 weeks after the last injection * any hemorrhagic trouble considered as a contraindication to intramuscular injection * history of severe adverse event after a vaccine administration including anaphylaxis and associated symptoms such as rash, respiratory issues, angioedema and abdominal pain, or history of allergic reaction that could be exacerbated by a vaccine component * participant vaccinated against tuberculosis within the past year

* documented sars-cov-2 infection ongoing or that occurred less than 3 months ago * known clinical allergy to polyethylene glycol (peg) * pregnant woman during first pregnancy quarter or lactating woman * platelet \<50 giga(g) g/l or neutrophils \<0.5 g/l at time of vaccination * vaccination within 4 weeks from the 1st injection or planning to receive an approved vaccine 4 weeks after the last injection * any hemorrhagic trouble considered as a contraindication to intramuscular injection * history of severe adverse event after a vaccine administration including anaphylaxis and associated symptoms such as rash, respiratory issues, angioedema and abdominal pain, or history of allergic reaction that could be exacerbated by a vaccine component * participant vaccinated against tuberculosis within the past year

documented sars-cov-2 infection ongoing or that occurred less than 3 months ago known clinical allergy to polyethylene glycol (peg) pregnant woman during first pregnancy quarter or lactating woman platelet <50 giga(g) g/l or neutrophils <0.5 g/l at time of vaccination vaccination within 4 weeks from the 1st injection or planning to receive an approved vaccine 4 weeks after the last injection any hemorrhagic trouble considered as a contraindication to intramuscular injection history of severe adverse event after a vaccine administration including anaphylaxis and associated symptoms such as rash, respiratory issues, angioedema and abdominal pain, or history of allergic reaction that could be exacerbated by a vaccine component participant vaccinated against tuberculosis within the past year

documented sars-cov-2 infection ongoing or that occurred less than 3 months ago known clinical allergy to polyethylene glycol (peg) pregnant woman during first pregnancy quarter or lactating woman platelet <50 giga(g) g/l or neutrophils <0.5 g/l at time of vaccination vaccination within 4 weeks from the 1st injection or planning to receive an approved vaccine 4 weeks after the last injection any hemorrhagic trouble considered as a contraindication to intramuscular injection history of severe adverse event after a vaccine administration including anaphylaxis and associated symptoms such as rash, respiratory issues, angioedema and abdominal pain, or history of allergic reaction that could be exacerbated by a vaccine component participant vaccinated against tuberculosis within the past year